pe0116
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 8, 2021 (NCT05800249)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
TNFRSF9 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05801237 | Phase 1/Phase 2 (Phase 2) | Sep 21, 2023 | Government of China |
| NCT06026501 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2023 | Government of China, Shanghai YingLi Pharmaceutical Co. Ltd. |
| NCT05800249 | Phase 1 | Mar 8, 2021 | Government of China |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 3 | 2 | 2 | 2021 |
| Shanghai YingLi Pharmaceutical Co. Ltd. | For profit | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1